scholarly journals Does dicamba exposure elicit a hormetic response in sensitive soybean?

cftm ◽  
2021 ◽  
Author(s):  
Mason C Castner ◽  
Jason K Norsworthy ◽  
Tom Barber ◽  
Edward Gbur ◽  
Trenton Roberts
Keyword(s):  
2009 ◽  
Vol 130 (6) ◽  
pp. 357-369 ◽  
Author(s):  
Aaron J. Przybysz ◽  
Keith P. Choe ◽  
L. Jackson Roberts ◽  
Kevin Strange

1998 ◽  
Vol 17 (8) ◽  
pp. 454-459 ◽  
Author(s):  
Angelo Turturro ◽  
Bruce Hass ◽  
Ronald W Hart

Hormesis can be considered as a parameter which has a non-monotonic relationship with some endpoint. Since caloric intake is such a parameter, and the impact of this parameter on risk assessment has been fairly well characterized, it can provide clues as to how to integrate the information from a hormetic parameter into risk assessments for toxicants. Based on the work with caloric intake, one could: (a) define a biomarker for hormetic effect; (b) integrate specific information on when in the animals lifespan the parameter is active to influence parameters such as survival; (c) evaluate component effects of the overall hormetic response; and (d) address the consequences of a non-monotonic relationship between the hormetic parameter and endpoints critical for risk assessment. These impacts on risk assessments have been characterized for chronic tests, but are also true for short-term tests. A priority is the characterization of the dose-response curves for hormetic parameters. This quantification will be critical in utilizing them in risk assessment. With this information, one could better quantitatively address the changes one expects to result from the hormetic parameter, and limit the uncertainty and variability which occurs in toxicity testing.


2017 ◽  
Vol 18 (2) ◽  
pp. 280 ◽  
Author(s):  
Jiuwei Cui ◽  
Guozi Yang ◽  
Zhenyu Pan ◽  
Yuguang Zhao ◽  
Xinyue Liang ◽  
...  

2000 ◽  
Vol 19 (6) ◽  
pp. 320-329 ◽  
Author(s):  
A Turturro ◽  
B S Hass ◽  
R W Hart

The question of whether caloric restriction (CR) is hormetic is addressed in terms of two common defini-tions of the term. In terms of the older definition, i.e., a growth-stimulatory effect when lower doses of a compound which resulted in growth inhibition at higher doses, CR is better characterized as a co-hormetic (i.e., a paradigm which at relatively “low doses,” in combina-tion with some stimulus, will evince increased growth (proliferation) and at higher “doses” will inhibit this increased proliferation) rather than a hormetic agent. Mechanisms such as cellular selection of cellular subpopulations, increases in receptor efficiency, and preservation of cellular proliferative potential can inter-act with agents and produce increased growth as long as the CR is not too severe. In terms of a broader definition, i.e., nonmonotonic dose-response behavior of a compound for any adverse response, CR appears to be hormetic, both as a result of body weight (BW) loss and other potential mechanisms. The impact of changes in BW, or frank CR, can be considered a component of every test for hormesis, and is thus capable for interaction with any other agent. The changes that BW loss (or CR) induce are so profound that any aspect of an agent's action-metabolism, pharmacokinetics, pharmacodynamics-can modulate the response of an organism to an agent. Similarly, other effects of a chemical that induce BW loss, e.g., physical activity or temperature dysregulation, can also induce dose-response curves that appear hormetic. The interaction of the hormetic agents of BW loss and CR can influence agent tests. Controlling these factors may make it possible to dissect the key components of a hormetic response. In addition, the effects of CR or BW loss appear to extrapolate well across species [Colman R, Kemnitz JW. Aging experi-ments using nonhuman primates. In: Yu BP (Ed), Methods in Aging Research. CRC Press, Boca Raton, FL, 1999, pp. 249-267]. Thus there is some reason to believe that these hormetic factors may be important for humans, and may already be a factor for tests of potentially adverse agents already conducted in humans.


2020 ◽  
Vol 206 ◽  
pp. 111123 ◽  
Author(s):  
Diwu Fan ◽  
Yujing Jing ◽  
Yongli Zhu ◽  
Sajjad Ahmad ◽  
Jiangang Han

2019 ◽  
Vol 251 ◽  
pp. 22-29 ◽  
Author(s):  
Pu Wang ◽  
Qin Xiang Ng ◽  
Bo Zhang ◽  
Zhikai Wei ◽  
Muhammad Hassan ◽  
...  

2012 ◽  
Vol 53 ◽  
pp. S126
Author(s):  
J. Ariza⁎ ◽  
L. Jódar ◽  
E.M. Mercken ◽  
B. Carboneau ◽  
R. de Cabo ◽  
...  

2010 ◽  
Vol 29 (12) ◽  
pp. 1032-1033 ◽  
Author(s):  
Jette F Young ◽  
Sumangala Bhattacharya

The lead article ‘‘Resveratrol commonly displays hormesis: occurrence and biomedical significance’’ underlines the hormetic response of resveratrol in many disease models. This commentary suggests that the greatest potential advantage of the positive effects of resveratrol for the broad population would be as prevention of disease development through oral administration in its original food matrix, although it still remains important to investigate the extent of resveratrol administration giving maximum beneficial effect for biomedical purposes. In relation to resveratrol ‘‘supplementation’’ through its natural environment further investigation of the impact of co-occurring bioactive compounds and matrix effects on hormetic responses of resveratrol is necessary for revealing mechanisms behind e.g. the ‘‘French paradox’’.


2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Brendan Gongol ◽  
Traci L. Marin ◽  
John D. Jeppson ◽  
Karina Mayagoitia ◽  
Samuel Shin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document